Functional microRNA high throughput screening reveals miR-9 as a central regulator of liver oncogenesis by affecting the PPARA-CDH1 pathway
暂无分享,去创建一个
D. Iliopoulos | G. Poultsides | C. Polytarchou | M. Hatziapostolou | A. Drakaki | J. Souglakos | C. Vorvis | V. Georgoulias
[1] Zhiyong Huang,et al. Loss of N-cadherin is associated with loss of E-cadherin expression and poor outcomes of liver resection in hepatocellular carcinoma. , 2015, The Journal of surgical research.
[2] Liwei Xie,et al. The long intergenic noncoding RNA UFC1, a target of MicroRNA 34a, interacts with the mRNA stabilizing protein HuR to increase levels of β-catenin in HCC cells. , 2015, Gastroenterology.
[3] C. Rangel-Escareño,et al. PPARα via HNF4α regulates the expression of genes encoding hepatic amino acid catabolizing enzymes to maintain metabolic homeostasis , 2015, Genes & Nutrition.
[4] Xiong Cai,et al. Up-regulation of miR-9 expression predicate advanced clinicopathological features and poor prognosis in patients with hepatocellular carcinoma , 2014, Diagnostic Pathology.
[5] G. Ning,et al. Aberrant miR199a-5p/caveolin1/PPARα axis in hepatic steatosis. , 2014, Journal of molecular endocrinology.
[6] S. Bauersachs,et al. Evidence for a role of E-cadherin in suppressing liver carcinogenesis in mice and men. , 2014, Carcinogenesis.
[7] Wei Zheng,et al. MicroRNA-148b expression is decreased in hepatocellular carcinoma and associated with prognosis , 2014, Medical Oncology.
[8] S. Zhang,et al. Abnormal expression of EMT-related proteins, S100A4, vimentin and E-cadherin, is correlated with clinicopathological features and prognosis in HCC , 2014, Medical Oncology.
[9] W. Yeung,et al. Perfluorooctanoate suppresses spheroid attachment on endometrial epithelial cells through peroxisome proliferator-activated receptor alpha and down-regulation of Wnt signaling. , 2013, Reproductive toxicology.
[10] N. Kiyosawa,et al. PPARα-mediated responses in human adult liver stem cells: In vivo/in vitro and cross-species comparisons , 2013, The Journal of Steroid Biochemistry and Molecular Biology.
[11] Kristen Jepsen,et al. Identification of Liver Cancer Progenitors Whose Malignant Progression Depends on Autocrine IL-6 Signaling , 2013, Cell.
[12] Xiaoming Liu,et al. MicroRNA-21 promotes hepatocellular carcinoma HepG2 cell proliferation through repression of mitogen-activated protein kinase-kinase 3 , 2013, BMC Cancer.
[13] A. Villanueva,et al. Emerging Signaling Pathways in Hepatocellular Carcinoma , 2012, Liver Cancer.
[14] Hsien-Da Huang,et al. MicroRNA-122 plays a critical role in liver homeostasis and hepatocarcinogenesis. , 2012, The Journal of clinical investigation.
[15] Xing-Xing He,et al. MicroRNA-375 targets AEG-1 in hepatocellular carcinoma and suppresses liver cancer cell growth in vitro and in vivo , 2012, Oncogene.
[16] A. Herling,et al. AVE8134, a novel potent PPARα agonist, improves lipid profile and glucose metabolism in dyslipidemic mice and type 2 diabetic rats , 2012, Acta Pharmacologica Sinica.
[17] Jian-Rong Yang,et al. MicroRNA-26a/b and their host genes cooperate to inhibit the G1/S transition by activating the pRb protein , 2011, Nucleic acids research.
[18] Kevin Struhl,et al. An HNF4α-miRNA Inflammatory Feedback Circuit Regulates Hepatocellular Oncogenesis , 2011, Cell.
[19] X. Bian,et al. The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2 , 2011, Gut.
[20] Meng-chao Wu,et al. Sphere-forming cell subpopulations with cancer stem cell properties in human hepatoma cell lines , 2011, BMC gastroenterology.
[21] Derek Y. Chiang,et al. MicroRNA-based classification of hepatocellular carcinoma and oncogenic role of miR-517a. , 2011, Gastroenterology.
[22] Hongbing Shen,et al. A potentially functional polymorphism in the promoter region of miR‐34b/c is associated with an increased risk for primary hepatocellular carcinoma , 2011, International journal of cancer.
[23] X. Chen,et al. Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma. , 2010, Cancer research.
[24] Y. Jeng,et al. Lin-28B expression promotes transformation and invasion in human hepatocellular carcinoma. , 2010, Carcinogenesis.
[25] Xiao‐hui Huang,et al. MicroRNA-9 reduces cell invasion and E-cadherin secretion in SK-Hep-1 cell , 2010, Medical oncology.
[26] Shinji Tanaka,et al. miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. , 2010, Carcinogenesis.
[27] C. Chi,et al. PPARγ/PGC-1α Pathway in E-Cadherin Expression and Motility of HepG2 Cells , 2009 .
[28] J. Yun,et al. Effects of MicroRNA‐29 on apoptosis, tumorigenicity, and prognosis of hepatocellular carcinoma , 2009, Hepatology.
[29] Kathryn A. O’Donnell,et al. Therapeutic microRNA Delivery Suppresses Tumorigenesis in a Murine Liver Cancer Model , 2009, Cell.
[30] Jian-Rong Yang,et al. MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. , 2009, Cancer research.
[31] D. Bartel. MicroRNAs: Target Recognition and Regulatory Functions , 2009, Cell.
[32] K. Mimori,et al. The search for cancer stem cells in hepatocellular carcinoma. , 2008, Surgery.
[33] Krista A. Zanetti,et al. Identification of metastasis‐related microRNAs in hepatocellular carcinoma , 2008, Hepatology.
[34] Thomas D. Schmittgen,et al. Association of MicroRNA Expression in Hepatocellular Carcinomas with Hepatitis Infection, Cirrhosis, and Patient Survival , 2008, Clinical Cancer Research.
[35] K. Ghoshal,et al. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. , 2007, Gastroenterology.
[36] C. Croce,et al. Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. , 2007, Cancer research.
[37] Derek Y. Chiang,et al. Genomics and signaling pathways in hepatocellular carcinoma. , 2007, Seminars in liver disease.
[38] M. Ikura,et al. Solution structure of the epithelial cadherin domain responsible for selective cell adhesion , 1995, Science.
[39] U. Plessmann,et al. Amino acid sequence characterization of mammalian vimentin, the mesenchymal intermediate filament protein , 1983, FEBS letters.
[40] T. W. Perry. The Effect of Genetic Variance of Nutritional Requirement of Animals: Proceedings of a 1974 Symposium , 1976 .
[41] D. Iliopoulos,et al. Therapeutically targeting microRNAs in liver cancer. , 2013, Current pharmaceutical design.
[42] A. Jemal,et al. Global Cancer Statistics , 2011 .
[43] C. Chi,et al. PPAR(gamma)/PGC-1(alpha) pathway in E-cadherin expression and motility of HepG2 cells. , 2009, Anticancer research.
[44] F. X. Bosch,et al. Epidemiology of Primary Liver Cancer , 1999, Seminars in liver disease.
[45] A. Jemal,et al. Global cancer statistics , 2011, CA: a cancer journal for clinicians.
[46] D. Woodfield. Hepatocellular carcinoma. , 1986, The New Zealand medical journal.